^
    14h
    Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically (clinicaltrials.gov)
    P=N/A, N=125, Recruiting, Dartmouth-Hitchcock Medical Center | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Ameluz (aminolevulinic acid)
    3d
    ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study (clinicaltrials.gov)
    P3, N=100, Recruiting, Steba Biotech S.A. | Trial primary completion date: Jun 2025 --> Mar 2026
    Trial primary completion date
    |
    Tookad (padeliporfin)
    3d
    Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease (clinicaltrials.gov)
    P1, N=5, Terminated, Roswell Park Cancer Institute | Active, not recruiting --> Terminated; low accrual
    Trial termination
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Photofrin (porfimer sodium)
    3d
    YAP1-driven tumor-like cancer-associated fibroblasts modulate biomechanics of pancreatic ductal adenocarcinoma. (PubMed, J Gastroenterol)
    YAP1 and tumor-like CAFs (tCAFs) play a pivotal role in driving desmoplasia in PDAC. YAP1 mediates the conversion of mCAFs to tCAFs and remodels the extracellular matrix (ECM), while high YAP1 activity in tCAFs regulates EMT induction to propel disease progression. Targeting the YAP1-tCAF axis can suppress desmoplasia and improve therapeutic outcomes. Magnetic resonance elastography (MRE) holds significant potential for non-invasive monitoring of stromal mechanics, offering a new perspective for stromal therapies in PDAC.
    Journal
    |
    YAP1 (Yes associated protein 1)
    |
    gemcitabine • Visudyne (verteporfin)
    6d
    X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma (clinicaltrials.gov)
    P1, N=52, Recruiting, Immunolight, LLC | N=20 --> 52
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • BRCA1 (Breast cancer 1, early onset) • BRCA (Breast cancer early onset)
    |
    HER-2 negative • ER negative
    |
    methoxsalen (X-PACT)
    10d
    MED12 Dictates Epithelial Ovarian Cancer Cell Ferroptosis Sensitivity via YAP-TEAD1 Signaling. (PubMed, Int J Mol Sci)
    Using CRISPR/Cas9-mediated knockout and rescue experiments in EOC cell lines, we demonstrate that MED12 deficiency significantly enhances sensitivity to ferroptosis inducers (RSL3 and Erastin), as evidenced by reduced IC50 values...Pharmacological inhibition of YAP with verteporfin or siRNA-mediated TEAD1 knockdown reverses ferroptosis sensitivity in MED12-deficient cells, confirming pathway specificity. These findings establish MED12 as a modulator of the YAP-TEAD1-ferroptosis axis and suggest that targeting this pathway could overcome chemoresistance in MED12-deficient EOC. Our work provides a mechanistic foundation for exploiting ferroptosis induction as a therapeutic strategy in ovarian cancer.
    Journal
    |
    CCN1 (Cellular Communication Network Factor 1) • CTGF (Connective tissue growth factor) • TEAD1 (TEA Domain Transcription Factor 1)
    |
    Visudyne (verteporfin) • erastin • RSL3
    22d
    New mitochondrial KV1.3 conjugates are potent and specific inducers of apoptosis in cancer models. (PubMed, Biomed Pharmacother)
    This study introduces a new structural class of mitochondria-targeted KV1.3 inhibitors with enhanced solubility compared to psoralen-based analogues. The unique mechanism of action, characterized by rapid depolarization and moderate ROS dependence, underscores their potential as selective anticancer agents. These findings warrant further investigation into in vivo efficacy and potential synergy with existing therapies.
    Preclinical • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • CASP7 (Caspase 7)
    29d
    VIRMA/IGF2BP3-mediated ANLN upregulation promotes intrahepatic cholangiocarcinoma growth by forming a positive feedback loop with RhoA/YAP1/TEAD1 signaling pathway. (PubMed, Cell Death Dis)
    Importantly, two clinical drugs, the RhoA inhibitor simvastatin and the YAP1/TEAD inhibitor verteporfin were determined to be the disruptors of this feed-forward signaling axis, inhibiting ICC tumor growth. These findings reveal the vital function of ANLN in ICC growth and provide promising treatment strategies for ICC.
    Journal
    |
    YAP1 (Yes associated protein 1) • RHOA (Ras homolog family member A) • ANLN (Anillin Actin Binding Protein) • IGF2BP3 (Insulin Like Growth Factor 2 MRNA Binding Protein 3) • TEAD1 (TEA Domain Transcription Factor 1) • VIRMA (Vir Like M6A Methyltransferase Associated)
    |
    Visudyne (verteporfin) • simvastatin
    1m
    Topical SGX302 for Mild-to-Moderate Psoriasis (clinicaltrials.gov)
    P2, N=15, Completed, Soligenix | N=47 --> 15 | Recruiting --> Completed
    Trial completion • Enrollment change
    1m
    Involvement of bile acids in cholangiocarcinoma progression via the Hippo-yes-associated protein signaling pathway. (PubMed, World J Gastrointest Oncol)
    The GDCA and DCA exert opposing effects on CCA progression through Hippo-YAP signaling. GDCA promotes tumor growth via YAP activation, while DCA inhibits these processes. YAP-targeted interventions demonstrate therapeutic potential, providing insights into new treatment strategies for CCA.
    Journal
    |
    LATS1 (Large Tumor Suppressor Kinase 1)
    |
    Visudyne (verteporfin)
    1m
    CUT-less: Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs) (clinicaltrials.gov)
    P4, N=327, Recruiting, University of Roma La Sapienza | Not yet recruiting --> Recruiting | Trial completion date: Feb 2030 --> Dec 2031 | Trial primary completion date: Dec 2027 --> Dec 2028
    Enrollment open • Trial completion date • Trial primary completion date • Head-to-Head
    |
    Cysview (hexaminolevulinate)
    1m
    EPIC- Extracorporeal Photopheresis (ECP) for Immune-related Colitis (clinicaltrials.gov)
    P2, N=0, Withdrawn, Therakos LLC | N=30 --> 0 | Suspended --> Withdrawn
    Enrollment change • Trial withdrawal • Checkpoint inhibition
    |
    Entyvio (vedolizumab)